SEC 10-Q
Shuttle Pharmaceuticals reports $2.1M net loss in Q3 2026 with 68% R&D cost increase, clinical trials advancing
Shuttle Pharmaceuticals' Q3 2026 filing shows accelerating R&D spend ($1.8M, +68% YoY) as the company advances its Phase 2 trial for SHP-309, a radiation sensitizer. While enrollment is progressing (42/60 patients), the current cash position ($4.2M) suggests urgent financing needs within 6-9 months. The IND submission timeline for a second candidate provides potential upside, but investors should monitor the burn rate ($700k/month) and enrollment pace (7 patients/month needed to hit target). The oncology sector will watch for validation of this niche mechanism, though near-term stock movement depends on financing news.
- Ticker
- SHPH
- Form
- 10-Q
Filing analysis
Shuttle Pharmaceuticals' Q3 2026 filing shows accelerating R&D spend ($1.8M, +68% YoY) as the company advances its Phase 2 trial for SHP-309, a radiation sensitizer. While enrollment is progressing (42/60 patients), the current cash position ($4.2M) suggests urgent financing needs within 6-9 months. The IND submission timeline for a second candidate provides potential upside, but investors should monitor the burn rate ($700k/month) and enrollment pace (7 patients/month needed to hit target). The oncology sector will watch for validation of this niche mechanism, though near-term stock movement depends on financing news.
All SHPH markets, filings and insider activity →
Source: Original SEC filing